|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008059,
umls-concept:C0021051,
umls-concept:C0031327,
umls-concept:C0036043,
umls-concept:C0039225,
umls-concept:C0039725,
umls-concept:C0086418,
umls-concept:C0132326,
umls-concept:C0164662,
umls-concept:C0205195,
umls-concept:C0209738,
umls-concept:C0237401,
umls-concept:C0302908,
umls-concept:C0524527,
umls-concept:C1521725,
umls-concept:C1707455
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-9-22
|
|
pubmed:abstractText |
Pediatric fixed-dose combinations (FDCs) are needed to facilitate antiretroviral therapy in children. We evaluated the relative bioavailability, safety, and therapeutic adequacy of a novel chewable pediatric FDC tablet of stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg), referred to as GPO-VIR S7, and compared it with the individual original brand-name liquid formulations in human immunodeficiency virus-infected Thai children.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1532-0987
|
|
pubmed:author |
pubmed-author:CapparelliEdmundE,
pubmed-author:ChokephaibulkitKulkanyaK,
pubmed-author:ChotpitayasunondhTaweeT,
pubmed-author:CresseyTim RTR,
pubmed-author:EksaengsriAcharaA,
pubmed-author:HongsiriwanSuchatS,
pubmed-author:IMPAACT P1056 Team,
pubmed-author:McIntoshKennethK,
pubmed-author:MuresanPetronellaP,
pubmed-author:PlipatNottasornN,
pubmed-author:PrasitsuebsaiWasanaW,
pubmed-author:SirisanthanaViratV,
pubmed-author:SmithMary ElizabethME,
pubmed-author:ToyeMariPatM,
pubmed-author:VanpraparNirunN,
pubmed-author:YogevRamR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
940-4
|
|
pubmed:meshHeading |
pubmed-meshheading:20453709-Administration, Oral,
pubmed-meshheading:20453709-Anti-HIV Agents,
pubmed-meshheading:20453709-Child,
pubmed-meshheading:20453709-Child, Preschool,
pubmed-meshheading:20453709-Cross-Over Studies,
pubmed-meshheading:20453709-Female,
pubmed-meshheading:20453709-HIV Infections,
pubmed-meshheading:20453709-Humans,
pubmed-meshheading:20453709-Infant,
pubmed-meshheading:20453709-Lamivudine,
pubmed-meshheading:20453709-Male,
pubmed-meshheading:20453709-Nevirapine,
pubmed-meshheading:20453709-Plasma,
pubmed-meshheading:20453709-Stavudine,
pubmed-meshheading:20453709-Tablets,
pubmed-meshheading:20453709-Thailand
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
|
|
pubmed:affiliation |
Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
